1. Accornero P, Radrizzani M, Care A, Mattia G, Chiodoni C, Kurrle R, Colombo MP (1998) HIV/gp 12 and PMA/ionomycin induced apoptosis but not activation induced cell death require PKC for Fas-L upregulation. FEBS Lett 436:467–465
2. Acs P, Wang QJ, Bogi K, Marquez AM, Lorenzo PS, Biro T, Szallasi Z, Mushinski JF, Blumberg PM (1997) Both the catalytic and regulatory domains of protein kinase C chimeras modulate the proliferative properties of NIH 3T3 cells. J Biol Chem 272:28793–28799
3. Adams LM, Dykes D, Harrison SD, Saleh J, Saah L (1993) Combined effect of the chemopotentiator SPC-100270, a protein kinase C (PKC) inhibitor, and doxorubicin (dox) or cisplatin (cis) on murine isografts and human tumor xenografts. Proc Am Assoc Cancer Res 34:410, 2448
4. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland RC, Koi N, Fishel R, Howell SB (1996) Loss of DNA mismatch repair. in acquired resistance to cisplatin. Cancer Res 56:3087–3090
5. Aftab DT, Yang JM, Hait WN (1994) Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. Oncol Res 6:59–70